Development of a rational scale to assess the harm of drugs of potential misuse, The Lancet, 2007 (Photo credit: Wikipedia)
It’s time to let scientists study whether LSD, marijuana and ecstasy can ease psychiatric disorders
Discovery of new psychiatric medication, whether for the treatment of depression, autism or schizophrenia, is at a virtual standstill. As just one example, the antidepressants on the market today are no more effective at reversing the mood disorder than those that first became available in the 1950s.
New thinking is desperately needed to aid the estimated 14 million American adults who suffer from severe mental illness. Innovation would likely accelerate if pharmacologists did not have to confront an antiquated legal framework that, in effect, declares off-limits a set of familiar compounds that could potentially serve as the chemical basis for entire new classes of drugs.
LSD, ecstasy (MDMA), psilocybin and marijuana have, for decades, been designated as drugs of abuse. But they had their origins in the medical pharmacopeia. Through the mid-1960s, more than 1,000 scientific publications chronicled the ways that LSD could be used as an aid to make psychotherapy more effective. Similarly, MDMA began to be used as a complement to talk therapy in the 1970s. Marijuana has logged thousands of years as a medicament for diseases and conditions ranging from malaria to rheumatism.
National laws and international conventions put a stop to all that. The Controlled Substances Act of 1970 declared that these drugs have “no currently accepted medical use” and classified them in the most stringently regulated category of controlled substances: Schedule I. The resulting restrictions create a de facto ban on their use in both laboratories and clinical trials, setting up a catch-22: these drugs are banned because they have no accepted medical use, but researchers cannot explore their therapeutic potential because they are banned. Three United Nations treaties extend similar restrictions to much of the rest of the world.
The decades-long research hiatus has taken its toll. Psychologists would like to know whether MDMA can help with intractable post-traumatic stress disorder, whether LSD or psilocybin can provide relief for cluster headaches or obsessive-compulsive disorder, and whether the particular docking receptors on brain cells that many psychedelics latch onto are critical sites for regulating conscious states that go awry in schizophrenia and depression.
The Latest on: Psychoactive Drug Research
via Google News
The Latest on: Psychoactive Drug Research
- Medical marijuana is booming in Florida, but the industry is nervous. Here’s why.on March 5, 2021 at 6:15 am
A bill capping THC, the main psychoactive compound in marijuana, and a landmark Florida Supreme Court case could change the game in Florida.
- Medical Cannabis in Portuguese Pharmacies – This Aprilon March 4, 2021 at 7:43 am
It is now two years after Portugal passed its medical marijuana bill, allowing access to cannabis medicines for those in need. And it looks like medical cannabis will finally be available in ...
- PsyBio Therapeutics Announces Retention of Market Makeron March 4, 2021 at 5:12 am
PsyBio Therapeutics Corp. (TSXV:PSYB) (“PsyBio” or the “Company”), a leader in the field of psychedelic research and drug development, announces that, subject to the receipt of approval by the TSX ...
- PsyBio Therapeutics Announces Retention of Market Maker TSX Venture Exchange:PSYBon March 4, 2021 at 3:48 am
PsyBio Therapeutics Corp. (TSXV:PSYB) (“PsyBio” or the “Company”), a leader in the field of psychedelic research and drug development, announces that, subject to the receipt of approval by the TSX ...
- MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injuryon March 4, 2021 at 12:43 am
This potential treatment opportunity was confirmed by the company's bioinformatics platform, PsyCollageVANCOUVER, BC, March 4, 2021 /PRNewswire/ ...
- Investors: The Marijuana Boom Is Nowon March 3, 2021 at 10:58 am
Marijuana will provide the basis for many of tomorrow's blockbuster drugs. David Borun shows you how to invest in this burgeoning industry.
- Are you microdosing psychedelics? The benefits might be a placebo effecton March 3, 2021 at 12:38 am
You know how taking small doses of a psychedelic drug every few days is all the rage among a certain set of affluent types with good drug dealers? See: Ayelet Waldman’s book, A Really Good Day: How ...
- PsyBio Therapeutics is pioneering the next generation of targeted psychoactive medicationson February 25, 2021 at 5:30 am
CEO Evan Levine said the biotechnology company has received a “tremendous amount of investment interest from top tier health care funds in ...
- Biomind Research Corp. and Crosswinds Holdings Inc. Announce Definitive Agreement to Complete Reverse Takeoveron February 22, 2021 at 10:09 am
Toronto, Ontario-- (Newsfile Corp. - February 22, 2021) - Crosswinds Holdings Inc. (TSX: CWI) (" Crosswinds ") and Biomind Research Corp. (" Biomind " or the " Company ") are pleased to announce the ...
- Research shows that, genetically, high-CBD “hemp” plants are mostly marijuanaon February 22, 2021 at 9:07 am
Traditionally, cannabis plants are split into two varieties: a drug-type grown for psychoactive or intoxicating properties (i.e., marijuana) and a hemp-type used to make industrial products like fiber ...
via Bing News